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Abstract
Background: Despite the burgeoning burden of diabetes mellitus (DM) and cardiovascular diseases (CVD) in low
and middle income countries (LMIC), access to affordable essential medicines and diagnostic tests for DM and CVD
still remain a challenge in clinical practice. The Access to Cardiovascular diseases, Chronic Obstructive pulmonary
disease, Diabetes mellitus and Asthma Drugs and diagnostics (ACCODAD) study aimed at providing contemporary
information about the availability, cost and affordability of medicines and diagnostic tests integral in the
management of DM and CVD in Uganda.
Methods: The study assessed the availability, cost and affordability of 37 medicines and 19 diagnostic tests in 22
public hospitals, 23 private hospitals and 100 private pharmacies in Uganda. Availability expressed as a percentage,
median cost of the available lowest priced generic medicine and the diagnostic tests and affordability in terms of
the number of days’ wages it would cost the least paid public servant to pay for one month of treatment and the
diagnostic tests were calculated.
Results: The availability of the medicines and diagnostic tests in all the study sites ranged from 20.1% for unfractionated
heparin (UFH) to 100% for oral hypoglycaemic agents (OHA) and from 6.8% for microalbuminuria to 100% for urinalysis
respectively. The only affordable tests were blood glucose, urinalysis and serum ketone, urea, creatinine and uric acid.
Parenteral benzathine penicillin, oral furosemide, glibenclamide, bendrofluazide, atenolol, cardiac aspirin, digoxin,
metformin, captopril and nifedipine were the only affordable drugs.
Conclusion: This study demonstrates that the majority of medicines and diagnostic tests essential in the management
of DM and CVD are generally unavailable and unaffordable in Uganda. National strategies promoting improved access
to affordable medicines and diagnostic tests and primary prevention measures of DM and CVD should be prioritised in
Uganda.
Keywords: Availability, Cost, Affordability, Diabetes mellitus, Cardiovascular diseases, Low and middle income countries
* Correspondence: kibirigedavis@gmail.com
1Department of Medicine, Uganda Martyrs Hospital Lubaga, P.O.BOX 7146
Kampala, Uganda
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kibirige et al. International Journal for Equity in Health  (2017) 16:154 
DOI 10.1186/s12939-017-0651-6
Background
Globally, the prevalence of diabetes mellitus (DM) and
cardiovascular diseases (CVD) has significantly reached
epidemic levels especially in the low and middle income
countries (LMIC) [1, 2]. This poses a colossal public
health threat. Both DM and CVD adversely affect prod-
uctivity, reduce quality of life, increase rates of mortality
and cause a massive economic strain to a nation’s health
systems, families and individuals [3].
Challenges like suboptimal screening, diagnosis and
management of DM and CVD coupled with low access
to affordable essential medicines and diagnostic tests
remain frequent in clinical practice in LMIC [4–11].
Improved access to affordable essential medicines and
diagnostic tests is an integral component of optimal
management of DM and CVD [12]. This directly reduces
morbidity and mortality due to DM and CVD.
Due to significant socio-economic and lifestyle
changes coupled with the drastic population growth,
Uganda is currently experiencing an epidemiological
transition from communicable diseases (CD) like tuber-
culosis and HIV to non communicable diseases (NCD)
like DM and hypertension (HT) [13]. Two recently con-
cluded nationwide representative studies to determine
the burden of DM [14] and HT [15] in Uganda using
the WHO STEP-wise methodology documented the
prevalence of DM and HT of 1.4 and 26.4% respectively,
with the majority of the participants unaware of their
condition. Heart diseases notably hypertensive heart
disease, rheumatic heart disease and dilated cardiomyop-
athy and related complications like acute heart failure
and atrial fibrillation are frequently encountered in
clinical practice in Uganda [16–18].
Despite the increasing burden of DM and CVD in
Uganda, the structuring of the health system impedes
provision of optimal DM and CVD care. The majority of
lower tier public hospitals (health centres 1, 2, 3 and 4)
which are easily accessible to the general population are
more oriented towards management of CD as opposed
to NCD. Patients with NCD are often referred to higher
tier public hospitals (district referral or national referral
hospitals) and the costly private hospitals for further
management. Preliminary findings from 1 multicentre
study reported that the majority of these lower tier
Ugandan public hospitals lacked the recommended
national and international guidelines of management of
NCDs and essential medicines and diagnostic tests [19].
There is limited contemporary data about the avail-
ability, cost and affordability of medicines and diagnostic
tests integral in the management of DM and CVD in
Uganda. Annually, the Medicines Transparency Alliance
conducts an assessment of availability and affordability
of 40 essential medicines for CD and NCD in the 4
regions of Uganda using the World Health Organization
(WHO) and Health Action International (HAI) standar-
dised method. The most recent survey done in May to
June 2015 assessed only 5 NCD drugs (Glibenclamide
5 mg, Metformin 500 mg, Nifedipine retard 20 mg, Fur-
osemide 40 mg and Propranolol 40 mg) in 112 public,
private and private not-for-profit health facilities. The
availability of glibenclamide ranged from 36% in rural
private hospitals to 80% in urban private health facili-
tates while the availability of metformin ranged from
36% in rural private for profit health facilities to 90%
in urban public health facilities. Low availability of
nifedipine and Propranolol was noted in all the public
hospitals (≤55%) [20].
Using the WHO and HAI standardised method for
surveying medicine prices in LMIC [21], the ACCODAD
study sought to add to the existing information about
extent of availability, cost and affordability of medicines
and diagnostic tests of NCD in Uganda and in LMIC.
This information will be pivotal in influencing the
formulation and implementation of national policies
aimed at improving access to affordable medicines and
diagnostic tests for DM and CVD.
Methods
Study settings and selection of study sites
The ACCODAD study was conducted from 15th January
2017 to 28th February 2017 in 22 public hospitals, 23 pri-
vate hospitals and 100 privately owned pharmacies. The
health units were selected from each of the 4 regions of
Uganda (central, western, eastern and northern) using
random sampling method from the hospital and private
pharmacy registries of the Ministry of Health and National
Drug Authority (NDA), Republic of Uganda respectively.
The total number of public and private hospitals in
Uganda is 155. Two of these are national referral hospitals,
14 are regional referral hospitals and 139 are general
hospitals. In terms of ownership, 65 are government owned,
63 private not for profit (PNFP) and 27 are private for profit
[22]. The public hospitals offer free medical care to all
patients. They procure all their drugs, laboratory tests and
medical equipment from one central national procurement
institution called the National Medical Stores (NMS). The
NMS purchases the essential drugs and diagnostic tests
from qualified private suppliers through a locally publicised
tender process. Nevertheless, recurrent drug stock outs and
unavailability of key diagnostic tests remains a key chal-
lenge in the public hospitals. This compels patients to seek
medical treatment from the costly privately owned hospi-
tals, clinics and pharmacies. These procure their medicines
and diagnostic tests from several private distributors. The
NDA registry has a total of 599 registered privately owned
retail pharmacies and 90 private hospital pharmacies
dealing in human medicines. The majority of the private
pharmacies (>70%) are located in the central region [23].
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The public hospitals, private hospitals and private phar-
macies where the data was collected accounted for 34, 26
and 15% of total national registered public hospitals,
private hospitals and private pharmacies respectively. The
majority of the study sites were selected from the central
region of the country (N = 83, 57.2%) because it has the
greatest number of registered hospitals and privately
owned pharmacies. Study sites selected from the eastern,
western and northern region accounted for 15.9, 17.9 and
9% respectively.
Sample size estimation
Basing on one of the primary objectives of the ACCODAD
study i.e. to determine the availability of the medicines and
diagnostic tests of interest, the availability of 4 key medi-
cines in DM and CVD management (intermediate insulin
or insulitard®, losartan, simvastatin and isosorbide mononi-
trate) of 10% as reported by the study performed in
Western Cameroon was used as the prevalence (P) [6].
Using the formula: n = Z2P (1-P)/d2 where Z (normal
value corresponding to the 95% confidence interval) =1.96,
P = 0.1 and d = 0.05 (desired precision of estimation), a
sample size of 138 health units (hospitals and private
pharmacies) was obtained. The study sample size was
however, increased to 145.
Data collection
For the ACCODAD study, we collected information
about 37 medicines and 19 diagnostic tests significant in
the management of DM and CVD as highlighted by the
Ugandan local guideline and several international guide-
lines as highlighted below. The CVD of interest were
hypertension, coronary artery disease, stroke, dilated car-
diomyopathy, rheumatic heart disease, atrial fibrillation,
peripheral arterial disease, venous thromboembolism
and related complications like heart failure.
The selected medicines of interest are part of the WHO
essential medicines list for treatment of chronic diseases
in LMICs [24] and are recommended in the management
of DM and CVD by the 2012 Uganda clinical guidelines
[25], the 2017 American Diabetes Association guidelines
of standard of care of DM and related CVD [22] and the
recent European Society of Cardiology (ESC) guidelines of
management of atrial fibrillation, acute myocardial infarc-
tion, acute heart failure [26–29].
The respective medicine categories and medicines of
interest were oral hypoglycaemic agents (OHA) which
included metformin 1 g and 500 mg, glibenclamide 5 mg,
glimepiride 2 mg and pioglitazone 30 mg, angiotensin II
receptor blockers (ARB) which included losartan 50 mg
and telmisartan 40 mg, angiotensin converting enzyme in-
hibitors (ACEI) which included captopril 25 mg, thiazide
diuretics (D) which included bendrofluazide 5 mg, ARB-D
which included losartan-hydrochlorothiazide 50/12.5 mg
and telmisartan-hydrochlorothiazide 40/12.5 mg, loop
diuretics which included oral furosemide 40 mg and i.v.
furosemide 20 mg, calcium channel blockers (CCB) which
included nifedipine 10 mg and 20 mg and amlodipine
5 mg and 10 mg, statins which included simvastatin
20 mg, atovastatin 20 mg and rosuvastatin 10 mg, anti
platelet drugs which included cardiac aspirin 75 mg and
Clopidogrel 75 mg, low molecular weight heparin which
included enoxaparin 60 mg and 80 mg and beta blockers
which included atenolol 50 mg, bisoprolol 5 mg, nebivolol
5 mg and carvedilol 6.25 mg. Other surveyed medicines
included: parenteral benzathine penicillin, oral digoxin,
warfarin, spironolactone, hydralazine, soluble insulin,
intermediate insulin, pre mixed insulin, isosorbide mono-
nitrate and unfractionated heparin (UFH).
The selected diagnostic tests are part of the WHO
minimum workup tests for assessment and management
of cardiovascular (CV) risk [24] and are also recom-
mended by the 2017 American Diabetes Association
guidelines of standard of care of DM and related CVD
[22] and the recent European Society of Cardiology
(ESC) guidelines of management of atrial fibrillation,
acute myocardial infarction, acute heart failure [26–29].
These included: lipid profile, glycated haemoglobin
(HbA1c), serum uric acid, serum troponin, coagulation
profile, thyroid function tests, serum creatinine, serum
urea, serum electrolytes, serum ketones, microalbumi-
nuria, complete blood count, serum natriuretic peptides,
electrocardiography (ECG), echocardiography (ECHO),
chest X ray, liver function tests and urinalysis.
Data was collected using a pre tested questionnaire
based on the WHO and HAI standardised methods of
assessing medicine prices, availability and affordability in
LMIC [21] from 15th January 2017 to 28th February
2017. The data collection team underwent a brief training
before commencement of the study to improve quality
and standardisation of data.
Information about the availability of diagnostic tests
and any medicine in the respective medicine category
was obtained. The cost of performing each diagnostic
test and the monthly cost of the recommended dose of
the available lowest priced generic (LPG) medicine was
obtained in Uganda shillings (UgX) and then converted
to US dollars (USD) using the existing exchange rate at
the time of data collection (1 USD = 3600 UgX). The
obtained costs of the medicines were the retail prices
charged directly to the patients at the respective phar-
macies of the private hospitals and private pharmacies.
The cost of the medicines in the public hospitals was
not obtained since medical care is offered free of charge.
Data analysis
Availability of the medicines and diagnostic tests was
assessed by calculating the proportion of hospitals and
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private pharmacies in which any desired dose of the
medicine and diagnostic test was present on the day of
data collection at the study site. We defined availability
as low, moderate or high when the medicines and diag-
nostic tests of interest were available in <50, 50–79 and
≥80% of the study sites respectively. Availability of the
selected medicines and diagnostic tests was compared
between the study sites to determine any statistically
significant difference which was defined as a p value of
<0.05. The cost of the available LPG medicine was com-
pared to the cost of the available originator medicine.
The obtained unit retail prices of the medicines in
USD were converted to a median price ratio (MPR) by
dividing the median local price by an international refer-
ence price (IRP). The IRP is obtained from the Manage-
ment Sciences for Health International Drug Price
Indicator Guide which reports median prices of high
quality multisource medicines offered to LMIC countries
by different suppliers. The MPR is used to express how
much greater or less the median local medicine price is
than the IRP. An MPR of 3 would mean that the local
medicine price is three times greater than the IRP. For
patients’ medicine prices, MPR ≤ 1.5 were considered
reasonable pricing [30].
Affordability was estimated by calculating the number
of days’ wages required to purchase a one month course
of treatment or pay for a specific diagnostic test using
the average salary of the lowest paid government worker
in USD. Medicines and diagnostic tests that cost ≤3 days’
wages were considered affordable. The exchange rate of
the local currency (UgX) to USD used was the commer-
cial “buy” rate at the time of data collection of 1
USD = 3600 UgX. The lowest paid government worker
at the time of the study (scale U8 lower-non formal
education teachers) earned a gross salary of 198,793
UgX (USD 55.2). After tax deductions, this translated to
a net salary of 139,155 UgX (USD 38.7) per month or
4638.5 UgX (1.3 USD) daily [31].
Results
Availability of the medicines
Low, moderate and high availability was documented in 5
(23.8%), 3 (14.3%) and 13 (61.9%) of the 21 surveyed medi-
cines categories respectively. The availability of the
surveyed medicine categories ranged from 20.1% for
unfractionated heparin (UFH) to 100% for OHA. High
availability was noted for the majority of the key medicine
categories in the management of hypertension and cardiac
diseases i.e. ARBs, ACEI, D, CCB, statins, anti platelet
drugs and beta blockers. None of the insulin types was of
high availability. Soluble, intermediate and pre mixed insu-
lin was available in 68.8, 34.7 and 60.1% of all the study
sites respectively. Isosorbide nitrate, UFH and LMWH
were all of low availability (summarised in Table 1).
Availability of the diagnostic tests
With regard to the 19 diagnostic tests of interest, 8 (42.1%)
were of low availability, 3 (15.8%) were of moderate avail-
ability and 8 (42.1%) were of high availability. The availabil-
ity ranged from 6.8% for microalbuminuria to 100% for
urinalysis. Apart from electrocardiography (ECG) and lipid
profile testing which were available in only 54.6 and 65.9%
of the study hospitals, the rest of the recommended WHO
minimum tests for DM and CVD workup were of high
availability (random blood glucose tests-97.7%, serum
electrolytes-88.6% and urinalysis-100%). Glycated haemo-
globin (HbA1c) tests, a key test in DM diagnosis and mon-
itoring of glycaemic control in diabetes care was available
in only 43.2% of the study hospitals. The majority of vital
tests in cardiac evaluation (echocardiography, coagulation
profile, serum natriuretic peptides and troponin tests) were
of low availability (summarised in Table 1).
Comparison of the availability of selected medicines in
the different study sites
There were significant differences in the availability of
key medicines documented in the public hospitals and
the private hospitals and pharmacies. Low availability
was noted for these medicine categories in public hospi-
tals compared to the private hospitals and pharmacies:
ARBs, ARB-thiazide diuretics, statins, warfarin, LMWH,
UFH and nitrates (summarised in Table 2).
Comparison of the availability of selected diagnostic tests
in public and private hospitals
With regard to the diagnostic tests, a statistically signifi-
cant difference in the availability of lipid profile, HbA1c,
uric acid, troponin, coagulation profile and thyroid func-
tion tests was noted in the surveyed public hospitals com-
pared to the private hospitals. All the documented tests
were of low availability in the public hospitals. Tests for
serum ketones, microalbuminuria, serum natriuretic pep-
tides and ECHO were of low availability regardless of the
study site (summarised in Table 3).
Affordability of the study medicines and diagnostic tests
of interest
Selected medicines
The only affordable medicines were parenteral benzathine
penicillin 2.4 MU (0.3 days’ wages), oral furosemide 40 mg
(0.5 days’ wages), glibenclamide 5 mg (0.7 days’ wages),
bendrofluazide 5 mg (0.7 days’ wages), atenolol 50 mg
(0.7 days’ wages), cardiac aspirin 75 mg (0.9 days’
wages), digoxin 0.25 mg (1.4 days’ wages), metformin
500 mg (2.8 days’ wages), captopril 25 mg (2.8 days’
wages) and nifedipine 20 mg (2.8 days’ wages). The
most unaffordable medicines were enoxaparin 80 mg
(53.5 days’ wages), enoxaparin 60 mg (41.2 days’ wages)
and UFH (38.5 days’ wages).
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Monthly management of an adult diabetic patient with
the cheapest oral hypoglycaemic agents (Glibenclamide
5 mg and metformin 500 mg), ACEI (captopril 25 mg),
statin (simvastatin 20 mg) and anti platelet drug (cardiac
aspirin 75 mg) would cost a total of 15.8 USD; equivalent
to 12.2 days’ wages. The monthly cost increased to 19.1
USD or 14.7 days’ wages if glimepiride, a newer generation
sulphonylurea was used or to 21.3 USD or 16.4 days’ wages
if pre mixed insulin was used instead of a sulphonylurea.
Management of hypertension co-morbidity by adding
the cheapest CCB (nifedipine 20 mg) would cost 19.4
USD or 14.9 days’ wages. Secondary prevention of CVD
using the cheapest selective beta blocker (bisoprolol
5 mg), ACEI (captopril 25 mg), statin (simvastatin
20 mg) and anti platelet drug (cardiac aspirin 75 mg)
would cost a total of 18.3 USD per month which is
equivalent to 14.1 days’ wages (summarised in Table 4).
Median cost, pricing of the available LPG medicines and
their comparison with the available originator medicines
With regard to pricing as reflected by the MPR, the only
reasonably priced medicines were parenteral benzathine
penicillin (1.2), losartan 50 mg (0.8) and amlodipine
10 mg (1.5). The MPR ranged from 0.8 for losartan
50 mg to 11.1 for simvastatin (summarised in Table 4).
With the exception of Glucophage® (metformin) 1 g,
Insulitard® (intermediate insulin) and Mixtard® (pre
mixed insulin), all of the available originator medicine
brands cost more than the available LPG medicine
brands. One originator brand (Adalat 30 mg) cost up to
10 times the cost of the available LPG brand (nifedipine
20 mg) (summarised in Table 5).
Selected diagnostic tests
The only affordable tests were random blood glucose
measurement (1.1 days’ wages), urinalysis (1.3 days’
wages), serum ketone measurement (2.1 days’ wages),
serum uric acid measurement (2.1 days’ wages), serum
creatinine measurement (2.4 days’ wages) and serum
urea measurement (2.4 days’ wages). The most un-
affordable diagnostic tests were echocardiography and
serum natriuretic peptides that cost 33.1 and 40.6 days’
wages respectively.
The cost of performing the WHO recommended tests
for CV risk assessment and management (proteinuria,
ECG, FBG, lipid profile and serum electrolytes measure-
ment) was 33.5 USD or 25.8 days’ wages if urinalysis was
used. The cost increased to 44.3 USD or 34.1 days’ wages
if microalbuminuria was used instead of urinalysis. The
WHO CV risk monitoring tests (lipid profile, FBG and
Table 1 Availability of all the DM and CVD medicines and diagnostic tests in all the study sites
Medicines (N = 21 classes) Availability (%) Diagnostic tests (N = 19) Availability (%)
UFH 20.1 Microalbuminuria 6.8
Isosorbide mono nitrate 27.8 Serum ketones 11.4
LMWH 31.9 Serum natriuretic peptides 11.4
Intermediate insulin 34.7 Echocardiography 34.1
Hydralazine 47.2 Coagulation profile 36.4
Pre mixed insulin 60.1 Serum troponin testing 43.2
Warfarin 64.6 HbA1c testing 43.2
Soluble insulin 68.8 Thyroid function tests 43.2
ARB-thiazide diuretics 82.6 Electrocardiography 54.6
Digoxin 84.0 Uric acid testing 56.8
Statins 84.0 Lipid profile 65.9
ARB 86.8 Creatinine 86.4
Spironolactone 87.5 Urea 86.4
Benzathine penicillin 87.5 Serum electrolytes 88.6
Furosemide 89.6 Chest X-ray 88.6
Thiazide diuretics 94.4 Liver function tests 95.5
Anti platelet drugs 95.1 Glucometers 97.7
ACEI 96.5 CBC testing 97.7
Beta blockers 97.2 Urinalysis 100
CCB 99.3
OHA 100
UFH Unfractionated heparin, LMWH Low molecular weight heparin, ARB Angiotensin II receptor blockers, ACEI Angiotensin converting enzyme inhibitors, CCB
Calcium channel blockers, OHA Oral hypoglycaemic agents, HbA1c Glycated haemoglobin
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proteinuria) cost 23.6 USD/18.2 days’ wages or 12.8
USD/7.1 days’ wages when using microalbuminuria or
urinalysis respectively. Annual monitoring of adult dia-
betic patients using HbA1c measurement at least twice
a year, annual ECG, microalbuminuria and lipid profile
assessment as recommended by the ADA guidelines of
diabetes management would cost 58.2 USD or 44.8 days’
wages (summarised in Table 6).
Discussion
The ACCODAD study sought to provide contemporary
data about the availability, cost and affordability of medi-
cines and diagnostic tests integral in the management of
DM and CVD in Uganda, a low income developing country
in East Africa. To the best of our knowledge, this is the
largest study in Uganda to comprehensively investigate the
availability, cost and affordability of a substantial number of
medicines and diagnostic tests that play a fundamental role
in optimal DM and CVD management in clinical practice.
Availability of medicines and diagnostic tests
In our study, low and moderate availability (availability
of <80% in all study sites) was reported in 38.1% of the
medicines and 57.9% of the diagnostic tests of interest.
Several similar studies assessing access to medicines and
diagnostic tests of NCDs in LMIC have reported similar
findings of low availability of medicines and diagnostic
tests especially in the public sector [5–10].
In the study reported from Western Cameroon, high
availability defined as availability ≥80% was only noted
with 6 (27%) of the surveyed medicines (parenteral
benzathine penicillin 2.4 MU, oral furosemide 40 mg,
glibenclamide 5 mg, Actrapid/soluble insulin, metformin
500 mg and Mixtard). The majority of rural study sites
had low availability of medicines [6]. In comparison with
our study, with the exception of the soluble and pre
mixed insulin, high availability of >80% was documented
with parenteral benzathine penicillin, oral furosemide,
glibenclamide and metformin.
Table 2 Comparison of the availability of the DM and CVD medicines between the public hospitals, private hospitals and pharmacies
Availability of the medicines in %
Medicines Private hospitals (n = 23) Public hospitals (n = 22) Private pharmacy (n = 100) P value
A: Medicines with a statistically significant difference between study sites
ARBs 87.0 31.8 99.0 <0.001
ARB-thiazide diuretics 78.3 27.3 96.0 <0.001
Statins 87.0 18.2 98.0 <0.001
Warfarin 65.2 18.2 74.8 <0.001
Soluble insulin 100 81.8 58.6 <0.001
Thiazide diuretics 82.6 95.5 97.0 0.025
Spironolactone 91.3 68.2 90.9 0.012
LMWH 47.8 9.1 33.3 0.018
UFH 39.1 4.6 19.2 0.014
Isosorbide mono nitrate 30.4 4.6 32.3 0.030
B: Medicines with no statistically significant difference between study sites
Captopril 91.3 95.5 98.0 0.277
CCB 95.7 100 100 0.071
Beta blockers 95.6 100 97.0 0.650
Anti platelet drugs 91.3 91.0 97.0 0.317
Digoxin 91.3 81.2 82.3 0.579
Pre mixed insulin 69.6 77.3 54.1 0.080
Intermediate insulin 43.5 27.3 34.3 0.516
Benzathine penicillin 91.3 100 83.8 0.097
Loop duiretics 91.3 100 86.9 0.182
Hydralazine 65.2 45.6 43.4 0.166
OHA 100 100 100 1
UFH Unfractionated heparin, LMWH Low molecular weight heparin, ARB Angiotensin II receptor blockers, ACEI Angiotensin converting enzyme inhibitors, CCB
Calcium channel blockers, OHA Oral hypoglycaemic agents
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In another study that assessed the availability, pricing
and affordability of 5 key cardiovascular medicines
(atenolol, captopril, hydrochlorothiazide, losartan and
nifedipine) in 36 LMIC (Uganda inclusive), upper middle
income and high income countries found an overall poor
availability of these medicines. Only 26.3 and 57.3% of
the medicines were available in the public and private
sector respectively [7]. In another similar multicentre
study involving 90 primary care facilities in 8 LMIC,
some of the 12 surveyed CVD and DM medicines were
not available in some countries. Soluble and long acting
insulin was absent in all study sites in Benin, Eriteria,
Bhutan and Vietnam. Isosorbide mono nitrate was
absent in Benin, Eriteria, Sudan and Bhutan and simva-
statin and amlodipine were absent in Eriteria and
Bhutan [10]. Low availability of nitrates, intermediate
and pre-mixed insulin was also reported by our study
(27.8, 34.7 and 60.1% respectively).
With regard to the availability of diagnostic tests, cross
sectional studies in LMIC had reported similar findings
of low availability [5–9]. In one of these studies
performed in the Western Cameroon in 2012, high avail-
ability defined as availability ≥80% was only noted with
50% of the surveyed diagnostic tests (RBG, urinalysis,
serum creatinine, serum urea and CBC). Serum electro-
lytes, lipid profile and uric acid tests, HbA1c tests and
ECG were only available in 60, 40, 20 and 10% of all the
study sites [6].
Another multicentre study performed in 90 primary
care centres of 8 LMIC (Benin, Bhutan, Eritrea, Sri
Lanka, Sudan, Suriname, Syria, and Vietnam), lipid pro-
file testing was available only in 33, 25, 20, 14 and 8% of
all study sites in Sudan, Benin, Suriname, Syria and Sri
Lanka. Low availability of serum creatinine tests was also
reported in the majority of the study sites. Of all study
sites, serum creatinine tests were available in 58% in
Sudan, 33% in Benin, 10% in Suriname and 8% in Sri
Lanka. Lipid profile tests were absent in Eriteria and
Vietnam while serum creatinine tests were absent in
all study sites in Eriteria, Bhutan and Syria. Serum
troponin tests were absent in all the countries except
Benin and Sudan where it was available in only 8% of
the study sites [10].
Comparing with our study, we also reported similar
findings of low availability of uric acid, HbA1c, ECG and
troponin tests (all <60%).
Table 3 Comparison of the availability of the DM and CVD diagnostic tests between the private and public hospitals
Availability of the tests (%)
Test Private hospitals (n = 23) Public hospitals (n = 24) P value
A: Diagnostic tests with a statistically significant difference between study sites
Lipid profile 86.4 45.5 0.004
HbA1c 63.6 22.7 0.006
Uric acid 77.3 36.4 0.006
Serum troponin 68.2 18.2 0.001
Coagulation profile 59.1 13.6 0.002
Thyroid function tests 72.7 13.6 <0.001
B: Diagnostic tests with no statistically significant difference between study sites
Serum creatinine 95.5 77.3 0.079
Serum urea 95.5 77.3 0.079
Glucometers 100 95.5 0.312
Serum electrolytes 95.5 81.8 0.154
Serum ketones 13.6 9.1 0.635
Microalbuminuria 4.6 9.1 0.550
CBC 95.5 100 0.312
Serum natriuretic peptides 18.2 4.6 0.154
Echocardiography 45.5 22.7 0.112
Chest X-ray 95.5 81.8 0.154
Liver function tests 100 90.9 0.148
Electrocardiography 54.5 54.5 1
Urinalysis 100 100 NA
HbA1c Glycated haemoglobin, CBC Complete blood count
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Table 4 Median prices and affordability of the DM-CVD lowest priced generic drugs in both private hospitals and pharmacies
Medicine (N = 37) Median (IQR) price/tab
in Ug Shs
Median price/tab
in USD
IRP in USD MPR Monthly cost
in USD
Days’ wagesc
A: Affordable drugs according to calculated days’ wages (≤ 3)
Benzathine penicillin 2.4 MU 1500 (1500–2000) 0.42 0.3241 1.2 0.4 0.3
Furosemide tablet 40 mg 100 (100–100) 0.02 0.0061 3.3 0.6 0.5
Glibenclamide 5 mg 100 (100–200) 0.03 0.0042 7.1 0.9 0.7
Bendrofluazide 5 mg 100 (100–100) 0.03 0.0072 4.2 0.9 0.7
Atenolol 50 mg 100 (100–200) 0.03 0.0106 2.8 0.9 0.7
Cardiac aspirin 75 mg 150 (150–200) 0.04 0.0196 2.0 1.2 0.9
Digoxin tablet 0.25 mg 200 (200–300) 0.06 0.0148 4.1 1.8 1.4
Metformin 500 mg 200 (200–300) 0.06 0.0168 3.6 3.6 2.8
Captopril 25 mg 200 (200–300) 0.06 0.0216 2.8 3.6 2.8
Nifedipine 20 mg 200 (100–250) 0.06 0.0233 2.6 3.6 2.8
B: Unaffordable drugs according to the calculated days’ wages (> 3)
Amlodipine 5 mg 500 (400–500) 0.14 0.0321 4.4 4.2 3.2
Warfarin 5 mg 500 (500–500) 0.14 0.0369 3.8 4.2 3.2
Glimepiride 2 mg 500 (400–1000) 0.14 – – 4.2 3.2
Spironolactone 25 mg 500 (400–600) 0.14 0.0398 3.5 4.2 3.2
Furosemide i.v vial 20 mg 1000 (1000–1500) 0.28 0.0623 4.5 4.2 3.2
Hydralazine tablet 25 mg 300 (225–450) 0.08 0.0376 2.1 4.8 3.7
Telmisartan 40 mg 600 (500–800) 0.17 – – 5.1 3.9
Bisoprolol 5 mg 600 (500–800) 0.17 – – 5.1 3.9
Pioglitazone 30 mg 600 (500–800) 0.17 – – 5.1 3.9
Losartan 50 mg 700 (600–800) 0.19 0.2443 0.8 5.7 4.4
Soluble insulin 1vial 22,000 (20000–25,000) 6.11 0.7723 7.9 6.1 4.7
Amlodipine 10 mg 750 (700–800) 0.21 0.1414 1.5 6.3 4.9
Intermediate insulin 1vial 23,000 (20000–25,000) 6.39 0.7723 8.3 6.4 4.9
Pre mixed insulin 1vial 23,000 (21000–25,000) 6.39 0.6143 10.4 6.4 4.9
Clopidogrel 75 mg 800 (700–1100) 0.22 0.0736 3.0 6.6 5.1
Losartan H 62.5 mg 800 (700–900) 0.22 – – 6.6 5.1
Telmisartan H 52.5 mg 800 (700–1000) 0.22 – – 6.6 5.1
Nebivolol 5 mg 1000 (900–1300) 0.28 – – 8.4 6.5
Simvastatin 20 mg 1000 (900–1500) 0.28 0.0252 11.1 8.4 6.5
Isosorbide mono-nitrate 10 mg 1000 (985–1600) 0.28 0.0705 4.0 8.4 6.5
Atovastatin 20 mg 1200 (1000–2000) 0.33 0.0640 5.2 9.9 7.6
Rosuvastatin 10 mg 1200 (1000–2000) 0.33 – – 9.9 7.6
Carvedilol 6.25 mg 700 (600–900) 0.19 0.0445 4.3 11.4 8.8
Metformin 1000 mg 700 (500–800) 0.19 – – 11.4 8.8
UFHb 5000 units 20,000 (18000–20,000) 5.56 0.9055 6.1 50.0 38.5
LMWHa 60 mg 38,500 (34500–45,000) 10.69 2.8751 3.7 53.5 41.2
LMWHa 80 mg 50,000 (45000–60,000) 13.89 5.8025 2.4 69.5 53.5
IQR Inter-quartile range, aLMWH Low molecular weight heparin, bUFH Unfractionated heparin
cDays’ wages-number of days’ wages to cover the monthly costs of the selected drug
Kibirige et al. International Journal for Equity in Health  (2017) 16:154 Page 8 of 12
Affordability of medicines and diagnostic tests of interest
The majority of surveyed medicines and diagnostic tests
have also been reported to be unaffordable in most studies
in LMIC, similar to the findings of our study. Our study
findings documented that only 27% of the surveyed medi-
cines and 32% of the surveyed diagnostic tests were
affordable in Uganda.
In comparison, only 7 (32%) of the studied medicines
(oral aspirin 500 mg, hydrochlorothiazide 50 mg, fur-
osemide 40 mg, nifedipine 10 and 20 mg, glibenclamide
5 mg and metformin 500 mg) were affordable according
to the study definition of affordability i.e. monthly cost
of a medicine of ≤1 days’ wages of a lowest paid public
servant in the study performed in Western Cameroon
[6]. The most unaffordable medicines in this study were
Mixtard, simvastatin 20 mg and heparin 5000 IU costing
18.7 days’ wages, 30.5 days’ wages and 182.36 days’
wages respectively [6]. In our study, only 6 (16%) medi-
cines cost less than a days’ wages (parenteral benzathine
penicillin, oral furosemide, glibenclamide, bendrofluazide,
atenolol, and cardiac aspirin).
In another multicentre study by Mendis S et al. in 6
LMIC (Bangladesh, Malawi, Sri Lanka, Brazil, Nepal and
Pakistan) assessing availability and affordability of 32
medicines essential in CVD, DM, asthma, glaucoma and
palliative care, anti hypertensive management using
hydrochlorothiazide monotherapy and glycaemic therapy
using either glibenclamide or metformin was affordable
in all the 6 countries (cost ≤1 days’ wages). Using
intermediate insulin for DM management was unafford-
able with a monthly cost equivalent to 2.8 days’ wages in
Brazil, 4.7 days’ wages in Pakistan, 6.1 days’ wages in Sri
Lanka, 7.3 days’ wages in Nepal and 19.6 days’ wages in
Malawi. Secondary prevention of CVD with an oral
aspirin, statin, beta blocker and ACEI in this study was
also unaffordable in some countries. This combination
using a generic medicine would cost ≤1.6 days’ wages
in Sri Lanka and Bangladesh, ≤ 6.1 days’ wages in
Brazil, Pakistan and Nepal and 18.4 days’ wages in
Malawi. The cost of treatment in Malawi would
increase to 48.8 days’ wages if an innovator statin
brand was used [5]. In our study, the monthly cost of
combination therapy used in secondary CVD preven-
tion using the cheapest beta blocker, ACEI, statin and
cardiac aspirin was 14.1 days’ wages; almost similar to
the cost in Malawi.
Regarding diagnostic tests, only urinalysis and random
blood glucose tests cost less than 1.5 days’ wages in the
study by Jingi A et al. in Western Cameroon. Other key
tests recommended by the WHO in optimal DM and
CVD workup in this study like lipid profile tests cost
3.1–3.6 days’ wages and ECG cost 10.7 days’ wages.
Glycated haemoglobin (HbA1c), an important test in
diagnosis and monitoring of glycaemic control in dia-
betes care cost 12.6 days’ wages [6]. Comparing to our
study findings, serum electrolytes, lipid profile test,
HbA1c test and ECG cost 5.3 days’ wages, 7.5 days’
wages, 8.6 days’ wages and 10.7 days’ wages respectively.
Table 5 Comparison between the median prices of the originator and lowest priced generic medicines
Originator medicine (OM) Median (IQR) price
of OM in UgX
Median (IQR) price
of OM in USD
Name of LPG medicine Median (IQR) of the
LPG medicine (UgX)
Median (IQR) price
of LPG in USD
Micardis 40 mg 3700 (2000–4000) 1.0 (0.6–1.1) Telmisartan 40 mg 600 (500–800) 0.2 (0.1–0.2)
Co-Micardis 40/12.5 mg 4000 (2000–4500) 1.1 (0.6–1.3) Telmisartan-H 800 (700–1000) 0.2 (0.2–0.3)
Adalat 30 mg 2000 (1500–2500) 0.6 (0.5–0.7) Nifedipine 20 mg 200 (100–250) 0.1 (0.02–0.1)
Norvasc 5 mg 1000 (1000–2600) 0.3 (0.3–0.7) Amlodipine 5 mg 500 (400–500) 0.1 (0.1–0.1)
Norvasc 10 mg 1500 (1250–2800) 0.4 (0.3–0.8) Amlodipine 10 mg 750 (700–800) 0.2 (0.2–0.2)
Concor 5 mg 2500 (1800–2500) 0.7 (0.5–0.7) Bisoprolol 5 mg 600 (500–800) 0.2 (0.1–0.2)
Lipitor 20 mg 3000 (2000–4000) 0.8 (0.6–1.1) Atovastatin 20 mg 1200 (1000–2000) 0.3 (0.3–0.6)
Crestor 10 mg 3000 (2500–3500) 0.8 (0.7–1) Rosuvastatin 10 mg 1200 (1000–2000) 0.3 (0.3–0.6)
Bayer aspirin 100 mg 400 (300–500) 0.1 (0.1–0.1) Cardiac aspirin 75 mg 150 (150–200) 0.04 (0.04–0.1)
Glucophage 500 mg 400 (300–500) 0.1 (0.1–0.1) Metformin 500 mg 200 (200–300) 0.1 (0.1–0.1)
Glucophage 1000 mg 600 (525–800) 0.2 (0.2–0.2) Metformin 1000 mg 700 (500–800) 0.2 (0.1–0.2)
Amaryl 2 mg 1800 (1000–2000) 0.5 (0.3–0.6) Glimepiride 2 mg 500 (400–1000) 0.1 (0.1–0.3)
Actrapid 1 vial 23,000 (22000–25,000) 6.4 (6.1–6.9) Soluble insulin 1 vial 22,000 (20000–25,000) 6.1 (5.6–6.9)
Insulitard 1 vial 23,000 (22000–25,000) 6.4 (6.1–6.9) Intermediate insulin 23,000 (20000–25,000) 6.4 (5.6–6.9)
Mixtard 1 vial 23,000 (22000–25,000) 6.4 (6.1–6.9) Pre mixed insulin 23,000 (21000–25,000) 6.4 (5.8–6.9)
Clexane 60 mg 42,000 (35000–46,800) 11.7 (9.7–13) LMWH 60 mg 38,500 (34500–45,000) 10.7 (9.6–12.5)
Clexane 80 mg 60,000 (55000–69,000) 16.7 (15.3–19.2) LMWH 80 mg 50,000 (45000–60,000) 13.9 (12.5–16.7)
OM Originator medicine, LPG Lowest priced generic, IQR Inter-quartile range, LMWH Low molecular weight heparin, UgX Uganda shillings, USD US dollars
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There are several plausible explanations for the low
availability of medicines and diagnostic tests especially
in the public hospitals in our study. Some of these key
medicines are not included in the 2012 national essential
medicine list and the 2016 Uganda Clinical guidelines of
management of NCDs. Inadequate allocation of funds to
the health sector to enable procurement of most essen-
tial medicines and diagnostic tests, poor stock mainten-
ance, forecast inaccuracy and inefficient distribution
systems from the national central procurement institu-
tion could also explain the low availability in the public
and private sectors.
The study finding of the majority of medicines and
diagnostic tests being unaffordable in the private sector
could be explained by the lack of local legislation to
regulate the maximum retail prices of medicines and a
vibrant local pharmaceutical industry sector to produce
cheap quality generic medicines for chronic diseases.
Conclusions
The ACCODAD study evidently demonstrates that the
majority of medicines and diagnostic tests important in
DM and CVD care are largely unavailable and unafford-
able in Uganda. These study findings offer contemporary
information to guide pragmatic approaches to address
the inequity in access to affordable medicines and diag-
nostic tests that are essential in DM and CVD care in
Uganda. More emphasis should be directed towards
improving access to these essential medicines and diag-
nostic tests in the public sector by ensuring their procure-
ment by the mandated central procurement institution
(NMS): ARBs, statins, warfarin, heparins, nitrates, lipid
profile, HbA1c, uric acid, troponin, coagulation profile
and thyroid function tests.
Concerted efforts to reduce the cost of UFH, LMWH,
new generation beta blockers, statins and insulin in the
private sector should be encouraged. Generally, availability
and affordability of these medicines and diagnostic tests
can be improved in Uganda by improving procurement
efficiency, stock handling, forecast accuracy, ensuring
equitable financing to the health sector and regular updat-
ing of the national essential drug list and management
guidelines. Strategies like boosting local pharmaceutical
production of high quality generic DM and CVD medi-
cines and introduction of local laws to regulate retail
prices of medicines can assist in reducing the cost of
these medicines. Due to the high costs of secondary
and tertiary DM and CVD management, national
policies to promote primary prevention strategies of
NCD should be widely adopted.
Table 6 Cost and affordability of DM-CVD selected diagnostic/screening tests in the private hospitals
Test Median (IQR) price in UgX Median price in USD Monthly cost in USD Days’ wages for test
A: Affordable diagnostic tests
RBG 5000 (5000–6950) 1.4 1.4 1.1
Urinalysis 6250 (5000–10,000) 1.7 1.7 1.3
Serum ketones 10,000 (10000–10,000) 2.8 2.8 2.1
Serum uric acid 10,000 (10000–15,500) 2.8 2.8 2.1
Serum urea 11,000 (10000–19,900) 3.1 3.1 2.4
Serum creatinine 11,000 (10000–20,000) 3.1 3.1 2.4
B: Unaffordable diagnostic tests
CBC 15,000 (13000–20,000) 4.2 4.2 3.2
Serum electrolytes 25,000 (15000–30,000) 6.9 6.9 5.3
Coagulation profile 30,000 (20000–30,000) 8.3 8.3 6.4
Chest X-ray 30,000 (25000–45,000) 8.3 8.3 6.4
Lipid profile 35,000 (30000–41,000) 9.7 9.7 7.5
Liver function tests 36,000 (27500–47,850) 10.0 10.0 7.7
Serum HbA1c 40,000 (35000–40,000) 11.1 11.1 8.6
Microalbuminuria 45,000 (45000–45,000) 12.5 12.5 9.6
Electrocardiography 50,000 (40000–52,000) 13.8 13.8 10.7
Serum troponin 53,000 (45000–60,000) 14.7 14.7 11.3
Thyroid function tests 100,000(77500–149,000) 27.8 27.8 21.4
Echocardiography 155,000 (100000–175,000) 43.1 43.1 33.1
Serum natriuretic peptides 190,000 (150000–275,000) 52.8 52.8 40.6
RBG Random blood glucose, CBC Complete blood count, HbA1c Glycated haemoglobin, UgX Uganda shillings, USD US dollars
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Study limitations
Being a point in time study, variations in availability,
pricing and affordability of the medicines and diagnostic
tests was not put into consideration. We were unable to
obtain the procurement prices from the central procure-
ment institution, NMS to obtain the prices of the medi-
cines and diagnostic tests in the public hospitals. Using
the daily wage of the lowest paid unskilled government
to calculate affordability of medicines and diagnostic
tests has its limitations because a significant proportion
of the Ugandan population earns less than this amount.
Despite these limitations, the study has its strengths.
The standardised WHO/HAI methodology that was
used has been widely validated.
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